Open Outbreak

Zika virus disease

Also known as: Zika, ZIKV, Zika fever

Zika virus disease is an infection caused by Zika virus. It is spread mainly by the bite of infected Aedes mosquitoes, the same group that can spread dengue and chikungunya. WHO outbreak reports also note that sexual transmission can happen, but mosquito-borne spread remains the main route. Many infections cause no symptoms. When symptoms do occur, they are usually mild and often last less than a week. Common symptoms include fever, rash, red eyes, joint pain, and headache. The main public health concern is not usually severe illness in the infected adult. It is the risk of complications, especially congenital problems in babies when infection happens during pregnancy, and a link with Guillain–Barré syndrome, a rare nerve disorder. WHO reports say Zika can cause large epidemics when it reaches populations with little prior immunity. There is no licensed vaccine or specific antiviral treatment in the sources found here, so care is supportive and prevention depends mainly on avoiding mosquito bites and reducing mosquito breeding sites.

Key facts

TransmissionMainly by bites from infected Aedes mosquitoes; sexual transmission has also been reported. Many infections are asymptomatic (WHO 2021 says about 60–80%).
Incubationunknown
Case fatalityunknown; the overview source says no reported deaths during the initial infection.
Reproduction numberunknown
VaccineNo licensed vaccine found in the sources retrieved in this session.
TreatmentNo specific licensed antiviral treatment found in the sources retrieved in this session; treatment is supportive.
Reservoirunknown
Endemic regionsHistorically described in tropical Africa and Asia, with later spread in the Pacific and the Americas.

Transmission

Zika virus disease spreads mainly through the bite of infected Aedes mosquitoes. WHO outbreak reports describe this as the primary route. These mosquitoes are common in many warm climates and often bite during the day. WHO also notes that sexual transmission can occur. That matters because it means spread is not limited to mosquito season alone, even though mosquito-borne spread remains the main driver. In 2021, WHO wrote that about 60% to 80% of infections are asymptomatic or only mild, which makes outbreaks harder to spot early. A review in Science also described Zika as an emerging global threat with limited information in the early epidemic period, reflecting how hard it can be to measure spread accurately. Reliable figures for a single basic reproduction number, or R0, were not established in the sources retrieved here, so that figure is listed as unknown.

Symptoms and severity

Most Zika infections cause no symptoms. When symptoms do happen, they are usually mild and last less than seven days, according to the overview source retrieved here. Typical symptoms are fever, rash, red eyes, joint pain, and headache. For most adults, the illness is short and not severe. The bigger concern is uncommon but important complications. The overview source states that infection during pregnancy can cause microcephaly and other brain malformations in some babies. It also notes a link between adult infection and Guillain–Barré syndrome, a rare condition in which the immune system damages nerves and can cause weakness or paralysis. WHO outbreak assessments repeat these concerns, especially congenital syndrome in pregnancy. The sources retrieved did not provide a dependable overall case fatality figure, and WHO’s recent India report noted no associated microcephaly or Guillain–Barré syndrome among the 2024 cases reported there.

Treatment and vaccines

The sources retrieved here do not show any licensed vaccine for general use against Zika virus disease. A 2016 review focused on medical countermeasures stated that there were no licensed vaccines, therapies, or preventive drugs available for Zika virus infection and disease. Later review material retrieved in this session discusses research and development, but it does not document a licensed product. That means prevention still relies mainly on avoiding mosquito bites, controlling mosquitoes, and reducing exposure during pregnancy. For people who become ill, the sources support supportive care rather than a virus-specific treatment. In plain terms, that means rest, fluids, and treatment of symptoms rather than a drug that directly cures Zika. Because many Zika symptoms overlap with dengue and chikungunya, WHO also stresses laboratory capacity and differential diagnosis during outbreaks. No source retrieved here gave evidence for a licensed antiviral treatment, so treatment status is listed as supportive care only.

Where it occurs

The retrieved sources describe Zika as a disease that was first known in tropical Africa and Asia, then spread more widely into Pacific islands and the Americas. Review articles in this session describe small earlier outbreaks in eastern Asia and the Pacific, followed by the large epidemic that began in Brazil in 2015. WHO outbreak notices from 2015 and 2016 show how quickly reports appeared across the Americas and other regions once the epidemic expanded. More recent WHO notices show that transmission can still be detected outside the main 2015–2017 emergency period. Examples retrieved here include India in 2017, 2021, and 2025 reporting on 2024 cases, and France in 2019, where WHO assessed the national spread risk as low because Aedes aegypti was not established there. In practice, Zika risk is highest where competent Aedes mosquitoes are present and public health systems must distinguish it from dengue and chikungunya.

Recent history

This site’s archive count for Zika is 33 WHO notices since 1996, which fits the pattern in the retrieved WHO records: many notices clustered in 2015 and 2016, then fewer later reports. The archive list returned in this session shows rapid geographic expansion across the Americas, the Caribbean, and other regions during the 2015–2016 emergency period. After that wave, WHO notices became less frequent but did not stop. Retrieved items include France in 2019, India in 2021, and a 2025 WHO Disease Outbreak News item summarizing 151 cases reported in India during 2024 across Gujarat, Karnataka, and Maharashtra. WHO said no microcephaly or Guillain–Barré syndrome associated with that Indian outbreak had been reported as of 2024-12-31. WHO’s assessments in these later reports still stress that Zika can cause large epidemics when introduced into populations with little prior immunity and where Aedes mosquitoes are present.

What to watch

The clearest warning signs would be spread into new places where competent Aedes mosquitoes are established, especially places with little existing immunity. WHO reports repeatedly frame geographic spread to previously unaffected areas as important, even when the overall risk assessment does not immediately change. Another signal would be more evidence of non-mosquito spread, especially sustained human-to-human transmission beyond the already known sexual route. Public health teams would also watch closely for increases in congenital problems linked to infection during pregnancy, or more Guillain–Barré syndrome after outbreaks. Because Zika can look like dengue or chikungunya, failure to separate these diseases in testing can hide real spread, so laboratory capacity matters. Finally, vaccine or drug supply is not yet a buffer in the sources retrieved here, because no licensed vaccine or specific therapy was documented. That means prevention still depends heavily on surveillance, mosquito control, and rapid testing when cases appear.

Updated